



**CANACCORD GENUITY APPOINTS DR. JULIAN FENELEY AS HEAD OF
HEALTHCARE INVESTMENT BANKING, EUROPE**

Grows Canaccord Genuity's Healthcare investment banking practice

LONDON, 19 March 2013 – Canaccord Genuity is pleased to announce that Dr. Julian Feneley will be joining the company as Head of Healthcare Investment Banking, Europe. Julian has over 20 years of healthcare industry experience as an investment banker and as a CEO. He will lead Canaccord Genuity's coverage of the European Healthcare sector from London and will report to Adrian Haxby, Head of European Investment Banking.

"We are very pleased to welcome Julian's deep Healthcare expertise and experience to our growing Healthcare team. He will play a key role in further strengthening our advisory capabilities in this important sector," stated Alexis de Rosnay, CEO of Canaccord Genuity Limited.

Prior to accepting the role at Canaccord Genuity, Julian held leadership positions at public and private companies and investment banks. At JP Morgan, where he was a senior member of their Healthcare investment banking franchise in Europe, he advised on a number of pivotal cross-border transactions including the creation of Novartis, Pharmacia & Upjohn and AstraZeneca. He has supported clients across all healthcare sub-sectors including biotechnology, specialty pharmaceuticals, med-device, med-tech, diagnostics, and healthcare services, and worked on a broad range of transactions with companies at all stages of development. Julian has also led companies in the healthcare space in the US and the UK, including Britesmile, Inc. and Bioscience Managers (a biotechnology venture capital and corporate finance boutique).

Dr. Feneley is a qualified medical doctor from Guy's Hospital in London, and has worked extensively in both Europe and the US. He has an M.B.B.S., Bachelors of Medicine, Bachelors of Surgery and Honours degree in Medicine and Physiology from London University.

Adrian Haxby added: "Julian's medical background and entrepreneurial approach make him an excellent addition to Canaccord Genuity's Investment Banking team."

Julian's appointment follows the recruitment of Daniel Sharp and Dr. Matthijs Smith to the firm's Life Sciences team in Melbourne in October 2012, and Harrison Wehner as Managing Director covering healthcare in Boston, who joined in November 2012 from Citigroup.

ABOUT CANACCORD GENUITY:

Canaccord Genuity is the global full service investment banking division of Canaccord Financial Inc. (TSX: CF, LSE: CF.), offering institutional and corporate clients idea-driven investment banking, merger and acquisition, research, sales and trading services from offices in 12 countries worldwide. Our team of nearly 1,000 capital markets and advisory professionals has industry and transactional expertise in 18 key sectors of the global economy. We are committed to providing valued services to our clients throughout the entire lifecycle of their business and operating as a gold standard independent investment bank – expansive in resources and reach, but targeted in industry expertise, market focus and individual client attention.

More information is available at: www.canaccordgenuity.com

ABOUT CANACCORD FINANCIAL INC.:

Through its principal subsidiaries, Canaccord Financial Inc. is a leading independent, full-service financial services firm, with operations in two principal segments of the securities industry: wealth management and global capital markets. Since its establishment in 1950, Canaccord has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual, institutional and corporate clients through comprehensive investment solutions, brokerage services and investment banking services. Canaccord has offices in 13 countries worldwide, including Wealth Management offices located in Canada, Australia, the UK and Europe. Canaccord Genuity, the international capital markets division, operates in Canada, the US, the UK, France, Germany, Ireland, Italy, Hong Kong, mainland China, Singapore, Australia and Barbados.

Canaccord Financial Inc. is publicly traded under the symbol CF on the TSX and the symbol CF. on the London Stock Exchange.

FOR FURTHER INFORMATION CONTACT:

London media:

Bobby Morse or Ben Romney

Buchanan (London)

Phone: +44 (0) 207 466 5000, email: bobbym@buchanan.uk.com

North America media:

Scott Davidson

Executive Vice President, Global Head of Corporate Development and Strategy

Phone: 416-869-3875, email: scott.davidson@canaccord.com

For investor relations inquiries contact:

Jamie Kokoska

Vice President, Investor Relations & Communications

Phone: 416-869-3891, email: jamie.kokoska@canaccord.com